Kensey Nash buys IntraLuminal Therapeutics's assets for $8m
This article was originally published in Clinica
Executive Summary
Kensey Nash has acquired the assets of IntraLuminal Therapeutics (ILT), the Carlsbad, California-based developer of the Safe-Cross system designed to tackle difficult-to-treat chronic total occlusions (CTO), for $8m in cash.